RIGL Financial Facts
Income (loss) from operations: -22.74MTotal costs and expenses: 26.5M
See Full Income Statement
Deferred revenue: 0
Total assets: 88.64M
See Full Balance Sheet
Rigel Pharmaceuticals, Inc. (RIGL) Earnings
|
Expand Research on RIGL
| Next EPS Date | 4/30/24 | EPS Growth Rate | +62.5% |
|---|---|---|---|
| Average EPS % Beat Rate | +81.8% | Revenue Growth Rate | +21.1% |
| Average % Move 1-Wk after EPS | -3.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/5/20 |  |
Q120 | $0.13 | $0.13 | $0.00 | $55.76M | $56.71M | N/A |  | | Details |
| 3/7/23 | Q422 | $0.01 | -$0.09 | +$0.10 | $51.3M | $36.52M | N/A | | | Details | |
| 2/28/19 | |
Q418 | $0.02 | $0.03 | -$0.01 | $37.9M | $36.35M | N/A | | | Details |
| 3/5/24 | Q423 | $0.00 | -$0.02 | +$0.02 | $35.8M | $34.1M | N/A | | | Details | |
| 8/2/22 | Q222 | -$0.08 | -$0.12 | +$0.04 | $29.8M | $23.82M | N/A | | | Details | |
| 11/7/23 | Q323 | -$0.03 | -$0.07 | +$0.04 | $28.1M | $27.2M | N/A | | | Details | |
| 8/1/23 | Q223 | $0.04 | -$0.08 | +$0.12 | $26.89M | $25.7M | N/A | | | Details | |
| 5/2/23 | Q123 | -$0.08 | -$0.10 | +$0.02 | $26.1M | $23.55M | N/A | | | Details |
